Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
Novartis' Cosentyx receives MHRA approval for two types of juvenile idiopathic arthritis - PMLiVE
Novartis - YouTube
Moving Away from Asthma and COPD, Novartis Hones in on 20 Approvals by 2026 | BioSpace
Novartis Annual Results | Novartis
NOVN Stock Price and Chart — SIX:NOVN — TradingView
Cause and Effect | SIX
Drug used to treat advanced prostate cancer in short supply, Novartis says - CBS News
NOVN: Novartis AG Stock Price Quote - SIX Swiss Ex - Bloomberg
A World of Opportunity
Novartis - Wikipedia
Novartis CEO Targets 20 Key Drugs as Potential Blockbusters - DCAT Value Chain Insights
It Paid Doctors Kickbacks. Now, Novartis Will Pay a $678 Million Settlement. - The New York Times
Rick Carlson - Oncology Care Consultant (Breast Cancer) - Novartis | LinkedIn
Novartis to spin off generics business Sandoz next year | Reuters
BioCentury - Marti leaving Novartis Oncology legal team
Novartis offre à Sandoz son autonomie et une cotation sur SIX | Radio Lac
Six Former and Current Novartis AG Execs Charged With Bribing Doctors in Korea | BioSpace
Alcon becomes a separately traded standalone company | Novartis
